Jones Trading Starts Dyne Therapeutics (DYN) at Buy

Jones Trading analyst Catherine Novack initiates coverage on Dyne Therapeutics (NASDAQ: DYN) with a Buy rating and a price target of $30.00.

The analyst comments "We are initiating coverage of Dyne Therapeutics (ticker: DYN) with a Buy rating and $30 PT. Over the next 12 months, Dyne has 2 shots on goal in rare neuromuscular diseases: 1) Registrational Ph2 data in Exon 51 Duchenne Muscular Dystrophy (DMD) in late 2025; and 2) Registrational Ph2 data in Myotonic Dystrophy Type 1 (DM1) in mid-2026. Dyne's competitive edge is the FORCE platform, which increases muscle delivery using an antibody fragment. In DM1, Dyne is neck-and-neck with a late-stage program from Avidity (RNA, Not Rated), but Dyne looks superior on safety, splicing, and CNS manifestations (more details below). We forecast $3.0B in unadjusted worldwide peak sales in 2034 (25% market share, 65% POS). In Exon 51 DMD, the bar is on the floor; Sarepta's (SRPT, Not Rated) Exondys 51 was approved on 0.44% dystrophin at 48 weeks, while DYNE-251 showed 8.72% muscle content-adjusted dystrophin at 24 weeks, plus benefit on functional outcomes. We forecast $600M peak unadjusted US sales for Exon 51 DMD in 2032 (50% market share, 65% POS). Initiate Buy and $30 PT."

For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.

Shares of Dyne Therapeutics closed at $10.63 yesterday.

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• Morgan Stanley Downgrades Tryg A/S (TRYG:DC) (TGVSF) to Underweight
• Berenberg Starts Alm Brand A/S (ALMB:DC) at Hold